Stocktoria

Passage BIO, Inc. PASG

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-02-28

Passage BIO, Inc. statistics & valuation

Market cap$15.1M
P / B0.8×
Return on capital-125.8%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
2019202020212022202320242025
Operating margin (%)
2019202020212022202320242025
Return on equity (%)
-36.80% -58.20% -67.60% -91.70% -105.70% -242.70% 2019202020212022202320242025
Shares outstanding
4.3M 45.6M 54.2M 54.6M 54.9M 3.2M 3.2M 2019202020212022202320242025
Net debt ($)
2019202020212022202320242025
Share buybacks ($)
2019202020212022202320242025
Return on assets (%)
-25.50% -34.20% -52.20% -55.90% -67.80% -63.20% -73.10% 2019202020212022202320242025
Free cash flow margin (%)
2019202020212022202320242025
Debt / equity (×)
2019202020212022202320242025
EPS ($)
-$2.91 -$3.48 -$2.50 -$1.86 -$21.04 -$14.35 2019202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Return on assets-73.1%-63.2%-67.8%-55.9%-52.2%-34.2%-25.5%
Return on equity-242.7%-105.7%-91.7%-67.6%-58.2%-36.8%81.1%
Current ratio2.074.077.2210.7411.0214.9845.04

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.